Heavy menstrual bleeding: what works best in the long term?

  • Br J Gen Pract

  • from Pavankumar Kamat
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Levonorgestrel-releasing intrauterine system (LNG-IUS) was comparable to usual medical treatment for long-term symptom relief and surgery-free survival in patients with heavy menstrual bleeding (HMB).

Why this matters

  • There is a lack of long-term evidence regarding treatment of HMB in the primary care setting.

Study design

  • Multicentre, parallel, open-label trial.
  • Women with HMB (n=571) were randomly assigned to receive LNG-IUS or usual medical treatment (tranexamic/mefenamic acid, combined oestrogen–progestogen or progesterone alone).
  • Primary outcome: Patient reported Menorrhagia Multi-Attribute Scale (MMAS).
  • Funding: National Institute of Health Research.

Key results

  • There was a significant improvement in MMAS scores from the baseline in the LNG-IUS and usual treatment groups (mean increase, 44.9 and 43.4 points, respectively; P<.001).
  • There was no significant difference in the MMAS scores amongst both groups (3.9 points; P=.09).
  • 5-y surgery-free survival rates were high in both groups (80% and 77%; P=.6).

Limitations

  • Individual drugs were not compared with LNG-IUS.
  • Cessation or change in menstrual periods, or cessation of therapy could have affected results.